Company Profile
Imunon Stock Price, News & Analysis
- Ticker:
- IMNN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.58 USD (-0.63%)
Close
Last updated: August 6, 2026
8.99M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, IMNN closed down 0.63% at $1.58. No new same-company headline was identified in the current news window.
Company overview
DNA-Mediated Immunotherapy Company
IMUNON develops localized gene-based immunotherapies for cancer.
IMNN-001
IMNN-001 is a DNA plasmid encoding interleukin-12 delivered into the peritoneal cavity to stimulate antitumor immunity in advanced ovarian cancer.
OVATION Program
The Phase 3 OVATION 3 study adds IMNN-001 to frontline chemotherapy after Phase 2 results suggested an overall-survival benefit.
Future catalysts
Enrollment in the Phase 3 OVATION 3 study is expected to complete by the first quarter of 2029.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Imunon (IMNN)?
Imunon (IMNN) most recently closed at 1.58 USD, a -0.63% move versus the previous session.
What is the market cap of Imunon (IMNN)?
Imunon currently has a market capitalization of 8.99M USD on BioPharmSignal.
What does Imunon do?
DNA-Mediated Immunotherapy Company IMUNON develops localized gene-based immunotherapies for cancer. IMNN-001 IMNN-001 is a DNA plasmid encoding interleukin-12 delivered into the peritoneal cavity to stimulate antitumor immunity in advanced ovarian cancer. OVATION Program The Phase 3 OVATION 3 study adds IMNN-001 to frontline chemotherapy after Phase 2...
On which exchange is IMNN stock listed?
Imunon (IMNN) is associated with NASDAQ, United States, Biopharma.
What is IMNN-001?
IMNN-001 IMNN-001 is a DNA plasmid encoding interleukin-12 delivered into the peritoneal cavity to stimulate antitumor immunity in advanced ovarian cancer.
Which conditions is Imunon targeting with IMNN-001?
Imunon is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Imunon describe recent progress with IMNN-001?
Enrollment in the Phase 3 OVATION 3 study is expected to complete by the first quarter of 2029.
What is DNA-Mediated?
DNA-Mediated Immunotherapy Company IMUNON develops localized gene-based immunotherapies for cancer.